Published in Nat Chem Biol on December 01, 2013
T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol (2014) 0.95
Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem (2015) 0.87
New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol (2015) 0.80
Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy. PLoS One (2015) 0.76
Total synthesis of feglymycin based on a linear/convergent hybrid approach using micro-flow amide bond formation. Nat Commun (2016) 0.75
Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol (2017) 0.75
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature (1994) 7.13
An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science (1996) 5.93
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (1990) 5.41
Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science (1992) 4.74
Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol (2011) 4.31
HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell (1995) 3.64
Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science (1992) 3.64
The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell (1993) 3.44
The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science (1999) 3.23
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15
Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science (1993) 3.06
Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol (2003) 3.00
The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature (1995) 2.90
Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet (1988) 2.88
Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature (2004) 2.84
A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity (1996) 2.69
A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity (2004) 2.53
Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med (2011) 2.52
The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci U S A (2005) 2.47
Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature (2012) 2.46
Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med (2005) 2.27
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 2.27
Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci U S A (1991) 2.25
An antigenic peptide produced by peptide splicing in the proteasome. Science (2004) 2.20
An antigen produced by splicing of noncontiguous peptides in the reverse order. Science (2006) 2.18
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science (1997) 2.18
26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J (2001) 2.09
Selection of self-reactive T cells in the thymus. Annu Rev Immunol (2011) 1.98
Amide bond formation: beyond the myth of coupling reagents. Chem Soc Rev (2008) 1.91
Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity (2003) 1.89
Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics (2012) 1.79
Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med (1994) 1.69
The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med (1994) 1.67
Peptide coupling reagents, more than a letter soup. Chem Rev (2011) 1.58
TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol (1997) 1.36
Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med (1994) 1.36
Protein-peptide interactions. Curr Opin Struct Biol (1995) 1.28
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23
Comparative genetics of MHC polymorphisms in different primate species: duplications and deletions. Hum Immunol (2006) 1.22
Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity (2001) 1.21
Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell (2012) 1.21
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol (1999) 1.19
Thymoproteasome: probable role in generating positively selecting peptides. Curr Opin Immunol (2008) 1.14
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res (2003) 1.13
Thymic microenvironments for T-cell repertoire formation. Adv Immunol (2008) 1.11
Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med (1999) 1.05
Selective interaction of Ni with an MHC-bound peptide. EMBO J (1991) 1.03
Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J Immunol (2006) 1.03
Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease. J Exp Med (2013) 0.95
Dendritic cell-based nanovaccines for cancer immunotherapy. Curr Opin Immunol (2013) 0.93
The fate of the three subunits of major histocompatibility complex class I molecules. Eur J Immunol (1992) 0.92
A novel pathway of presentation by class II-MHC molecules involving peptides or denatured proteins important in autoimmunity. Mol Immunol (2012) 0.91
The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. Eur J Immunol (1997) 0.90
T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin Dev Immunol (2011) 0.89
Beta-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope. J Biol Chem (2001) 0.85
A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann N Y Acad Sci (1995) 0.84
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol (2008) 0.83
Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum. Eur J Immunol (1997) 0.83
Self-peptides in TCR repertoire selection and peripheral T cell function. Curr Top Microbiol Immunol (2014) 0.83
Probing molecular interactions within class II MHC Aq/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J Med Chem (2007) 0.81
Structural basis of metal hypersensitivity. Immunol Res (2013) 0.81
Immunotherapeutic strategies: the melanoma example. Immunotherapy (2009) 0.79
It's the peptide-MHC affinity, stupid. Cancer Cell (2013) 0.78
The 1995 Albert Lasker Medical Research Award. The class I and class II proteins of the human major histocompatibility complex. JAMA (1995) 0.77
Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol (2002) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell (2005) 2.76
Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem (2004) 2.75
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23
Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci U S A (2004) 2.09
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell (2013) 2.05
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol (2004) 1.86
Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin. Angew Chem Int Ed Engl (2010) 1.83
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem Biol (2011) 1.58
Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol Cell (2011) 1.56
An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains. Nat Struct Mol Biol (2011) 1.55
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
The deubiquitinating enzyme UCH-L3 regulates the apical membrane recycling of the epithelial sodium channel. J Biol Chem (2007) 1.43
On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J Am Chem Soc (2013) 1.32
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun (2013) 1.31
Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res (2008) 1.28
Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. J Biol Chem (2006) 1.26
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res (2006) 1.25
Recombination-induced tag exchange to track old and new proteins. Proc Natl Acad Sci U S A (2009) 1.23
Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21
Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog (2006) 1.17
Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol (2013) 1.16
Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci (2005) 1.16
Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMBO Rep (2012) 1.15
A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell (2011) 1.14
Automated online sequential isotope labeling for protein quantitation applied to proteasome tissue-specific diversity. Mol Cell Proteomics (2008) 1.13
Chemical evolution of autotaxin inhibitors. Chem Rev (2012) 1.12
Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-specific proteases. Chembiochem (2005) 1.07
Nonhydrolyzable ubiquitin-isopeptide isosteres as deubiquitinating enzyme probes. J Am Chem Soc (2010) 1.03
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther (2008) 1.01
Profiling proteasome activity in tissue with fluorescent probes. Mol Pharm (2007) 1.01
High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol (2009) 1.00
Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain (2013) 0.99
Discovery and optimization of boronic acid based inhibitors of autotaxin. J Med Chem (2010) 0.97
Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. FASEB J (2009) 0.95
Class I major histocompatibility complexes loaded by a periodate trigger. J Am Chem Soc (2009) 0.95
DUBs and disease: activity assays for inhibitor development. Curr Opin Drug Discov Devel (2008) 0.94
Early adipogenesis is regulated through USP7-mediated deubiquitination of the histone acetyltransferase TIP60. Nat Commun (2013) 0.94
Ubiquitin-based probes prepared by total synthesis to profile the activity of deubiquitinating enzymes. Chembiochem (2012) 0.93
Transpeptidation and reverse proteolysis and their consequences for immunity. Int J Biochem Cell Biol (2008) 0.92
Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr Protoc Immunol (2009) 0.92
A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents. Chembiochem (2011) 0.91
Chemistry-based functional proteomics: mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases. J Proteome Res (2004) 0.90
Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum (2013) 0.89
A native chemical ligation handle that enables the synthesis of advanced activity-based probes: diubiquitin as a case study. Chembiochem (2014) 0.89
UV-induced ligand exchange in MHC class I protein crystals. J Am Chem Soc (2009) 0.88
Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib. Mol Pharm (2012) 0.87
Structure-based design of novel boronic acid-based inhibitors of autotaxin. J Med Chem (2011) 0.87
Molecular characterization of ubiquitin-specific protease 18 reveals substrate specificity for interferon-stimulated gene 15. FEBS J (2014) 0.87
Ubiquitin proteasome system as a pharmacological target in neurodegeneration. Expert Rev Neurother (2006) 0.86
Synthesis and evaluation of a selective fluorogenic Pup derived assay reagent for Dop, a potential drug target in Mycobacterium tuberculosis. Chembiochem (2012) 0.85
Mycobacterium tuberculosis prokaryotic ubiquitin-like protein-deconjugating enzyme is an unusual aspartate amidase. J Biol Chem (2012) 0.85
Lower expression of catalytic and structural subunits of the proteasome contributes to decreased proteolysis in peripheral blood T lymphocytes during aging. Int J Biochem Cell Biol (2007) 0.83
Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish. Development (2012) 0.83
Quantifying cross-tissue diversity in proteasome complexes by mass spectrometry. Mol Biosyst (2010) 0.83
Technologies for MHC class I immunoproteomics. J Proteomics (2010) 0.81
Proteasome proteolytic profile is linked to Bcr-Abl expression. Exp Hematol (2009) 0.81
Phosphoproteomic analysis with a solid-phase capture-release-tag approach. Chem Biol (2005) 0.80
Development of an activity-based probe for autotaxin. Chembiochem (2010) 0.80
Applications for chemical probes of proteolytic activity. Curr Protoc Protein Sci (2004) 0.80
Fluorescence-based proteasome activity profiling. Methods Mol Biol (2012) 0.80
A multifunctional protease inhibitor to regulate endolysosomal function. ACS Chem Biol (2011) 0.79
Target specificity of the E3 ligase LUBAC for ubiquitin and NEMO relies on different minimal requirements. J Biol Chem (2013) 0.79
A modified epigenetics toolbox to study histone modifications on the nucleosome core. Chembiochem (2010) 0.79
Chemical proteomics profiling of proteasome activity. Methods Mol Biol (2006) 0.78
Development of a hypersensitive periodate-cleavable amino acid that is methionine- and disulfide-compatible and its application in MHC exchange reagents for T cell characterisation. Chembiochem (2013) 0.78
Drug discovery and assay development in the ubiquitin-proteasome system. Biochem Soc Trans (2010) 0.78
Catching a DUB in the act: novel ubiquitin-based active site directed probes. Curr Opin Chem Biol (2014) 0.78
Synthesis of atypical diubiquitin chains. Methods Mol Biol (2012) 0.75
Integrating chemical and genetic silencing strategies to identify host kinase-phosphatase inhibitor networks that control bacterial infection. ACS Chem Biol (2013) 0.75
Mechanism-based proteomics tools based on ubiquitin and ubiquitin-like proteins: crystallography, activity profiling, and protease identification. Methods Enzymol (2005) 0.75
Editorial overview: Molecular immunology: targeting the immune system. Curr Opin Chem Biol (2014) 0.75